Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice

Abstract

These results demonstrate that PD-1 is a biomarker for functional myeloma-specific T cells, and that activated and expanded PD-1⁺ T cells can be effective as ACT for myeloma. Furthermore, this strategy could be useful for treating other hematologic cancers.